{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:42:26Z","timestamp":1774953746507,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41409-019-0702-2","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T14:05:04Z","timestamp":1569593104000},"page":"595-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party"],"prefix":"10.1038","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-4040","authenticated-orcid":false,"given":"Abdul Hamid","family":"Bazarbachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Al Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose-Marie","family":"Hamladji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zina","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"702_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109:944\u201350.","journal-title":"Blood"},{"key":"702_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","volume":"21","author":"E Tavernier","year":"2007","unstructured":"Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907\u201314.","journal-title":"Leukemia"},{"key":"702_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N Gokbuget","year":"2012","unstructured":"Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032\u201341.","journal-title":"Blood"},{"key":"702_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","volume":"121","author":"SJ Forman","year":"2013","unstructured":"Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121:1077\u201382.","journal-title":"Blood"},{"key":"702_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532\u201343.","journal-title":"J Clin Oncol"},{"key":"702_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","volume":"46","author":"N Gokbuget","year":"2009","unstructured":"Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46:64\u201375.","journal-title":"Semin Hematol"},{"key":"702_CR7","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N Gokbuget","year":"2016","unstructured":"Gokbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524\u201333.","journal-title":"Haematologica"},{"key":"702_CR8","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113:3186\u201391.","journal-title":"Cancer"},{"key":"702_CR9","first-page":"85","volume":"1","author":"M Enrico","year":"2019","unstructured":"Enrico M, Francesco S, Francesco L. Treatment of adult patients with relapsed\/refractory b-cell philadelphia-negative acute lymphoblastic leukemia. Clin Hematol Int. 2019;1:85\u201393.","journal-title":"Clin Hematol Int"},{"key":"702_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95:589\u201396.","journal-title":"Haematologica"},{"key":"702_CR11","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cncr.30604","volume":"123","author":"J Pavlu","year":"2017","unstructured":"Pavlu J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017;123:1965\u201370.","journal-title":"Cancer"},{"issue":"4","key":"702_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41409-018-0288-0","volume":"54","author":"Vipul Sheth","year":"2018","unstructured":"Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, et al. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan\/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP\/EBMT analysis. Bone Marrow Transplant. 2018;54:531\u20139.","journal-title":"Bone Marrow Transplantation"},{"key":"702_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/ajh.25281","volume":"93","author":"A Fraccaroli","year":"2018","unstructured":"Fraccaroli A, Prevalsek D, Fritsch S, Haebe S, Bucklein V, Schulz C, et al. Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed\/refractory AML\/MDS. Am J Hematol. 2018;93:1524\u201331.","journal-title":"Am J Hematol"},{"key":"702_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ajh.25004","volume":"93","author":"J Decroocq","year":"2018","unstructured":"Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, et al. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: a study from the societe Francophone de Greffe de Moelle et de Therapie Cellulaire. Am J Hematol. 2018;93:416\u201323.","journal-title":"Am J Hematol"},{"key":"702_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjh.14428","volume":"176","author":"O Ringden","year":"2017","unstructured":"Ringden O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, et al. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2017;176:431\u20139.","journal-title":"Br J Haematol"},{"key":"702_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bbmt.2016.11.002","volume":"23","author":"F Malard","year":"2017","unstructured":"Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, et al. Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the acute leukemia working party of the european group for blood and marrow transplantation. Biol Blood Marrow Transpl. 2017;23:278\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"702_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12185-011-0919-3","volume":"94","author":"K Arita","year":"2011","unstructured":"Arita K, Kondo T, Sugita J, Shigematsu A, Shiratori S, Wakasa K, et al. Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int J Hematol. 2011;94:291\u20135.","journal-title":"Int J Hematol"},{"key":"702_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Socie G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139\u201349.","journal-title":"Haematologica"},{"key":"702_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3324\/haematol.2016.150326","volume":"102","author":"M Mohty","year":"2017","unstructured":"Mohty M, Malard F, Blaise D, Milpied N, Socie G, Huynh A, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica. 2017;102:184\u201391.","journal-title":"Haematologica"},{"key":"702_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"702_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"702_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/leu.2011.230","volume":"26","author":"TH Terwey","year":"2012","unstructured":"Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012;26:536\u201342.","journal-title":"Leukemia"},{"key":"702_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610\u20131.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"702_CR24","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","volume":"25","author":"Olle Ringd\u00e9n","year":"2019","unstructured":"Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients over 69 years of age with acute myeloid leukemia: on behalf of the acute leukemia working party of the Ebmt. Biol Blood Marrow Transplant. 2019. pii: S1083-8791(19)30362-3. \nhttps:\/\/doi.org\/10.1016\/j.bbmt.2019.05.037\n\n. [Epub ahead of print].","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"702_CR25","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.bbmt.2016.09.007","volume":"22","author":"K Mitsuhashi","year":"2016","unstructured":"Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, et al. Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2016;22:2194\u2013200.","journal-title":"Biol Blood Marrow Transpl"},{"key":"702_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/bmt.2015.278","volume":"51","author":"X Cahu","year":"2016","unstructured":"Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socie G, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transpl. 2016;51:351\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"702_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"S Eder","year":"2017","unstructured":"Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, et al. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: a matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:997\u20131003.","journal-title":"Am J Hematol"},{"key":"702_CR28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","volume":"24","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, et al. Intravenous Busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2018;24:726\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"702_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2991\/chi.d.190218.002","volume":"1","author":"RP Rashmika","year":"2019","unstructured":"Rashmika RP, Sorab G, Sebastian G, Bipin NS, Gabor V, Arnon N, et al. Current status and perspectives of irradiation-based conditioning regimens for patients with acute leukemia undergoing hematopoietic stem cell transplantation. Clin Hematol Int. 2019;1:19\u201327.","journal-title":"Clin Hematol Int"},{"issue":"14","key":"702_CR30","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"Hagop M. Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"702_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"702_CR32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","volume":"17","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:897\u2013901.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"702_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000495558","volume":"141","author":"F El Chaer","year":"2019","unstructured":"El Chaer F, Holtzman NG, Sausville EA, Law JY, Lee ST, Duong VH, et al. Relapsed philadelphia chromosome-positive Pre-B-ALL after CD19-directed CAR-T cell therapy successfully treated with combination of blinatumomab and ponatinib. Acta Haematol. 2019;141:107\u201310.","journal-title":"Acta Haematol"},{"issue":"5","key":"702_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15973","volume":"186","author":"Arnon Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019;186:767\u201376.","journal-title":"British Journal of Haematology"},{"key":"702_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"702_CR36","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25:1142\u20136.","journal-title":"Clin Cancer Res"},{"key":"702_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","volume":"13","author":"MH Cohen","year":"2008","unstructured":"Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Oncologist. 2008;13:709\u201314.","journal-title":"Oncologist"},{"key":"702_CR38","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738\u201347.","journal-title":"Blood"},{"key":"702_CR39","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/j.clml.2018.07.289","volume":"18","author":"J El-Cheikh","year":"2018","unstructured":"El-Cheikh J, Moukalled NM, El Darsa H, Massoud R, Kanj SS, Mahfouz R, et al. Feasibility of the combination of venetoclax and asparaginase-based chemotherapy for adult patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:e441\u2013e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"702_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2991\/chi.d.190219.001","volume":"1","author":"J Elad","year":"2019","unstructured":"Elad J. Relapse and resistance to CAR-T cells and blinatumomab in hematologic malignancies. Clin Hematol Int. 2019;1:79\u201384.","journal-title":"Clin Hematol Int"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0702-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0702-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0702-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:15:57Z","timestamp":1684617357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0702-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0702-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}